We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clorox Pre-Q4 Earnings Send Mixed Signals: Time to Accumulate Shares?
Read MoreHide Full Article
Key Takeaways
CLX is expected to post Q4 revenue of $1.94B and EPS of $2.25, up 2% and 23.6% year over year.
Clorox's IGNITE strategy and premium launches like Scentiva support growth despite a tough consumer landscape.
Gross margin is projected to be 44% in Q4, aided by cost discipline and retailer inventory builds.
The Clorox Company (CLX - Free Report) is slated to report fiscal fourth-quarter 2025 earnings on July 31, after market close. The company is expected to register year-over-year top-and-bottom-line growth when it posts fourth-quarter numbers.
The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $1.94 billion, indicating an increase of 2% from the prior-year quarter. The consensus mark for quarterly earnings per share (EPS) has increased by a penny in the past seven days to $2.25 per share, indicating an increase of 23.6% from the figure reported in the year-ago quarter.
The Clorox Company Price, Consensus and EPS Surprise
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $7.1 billion, indicating a decline of 0.5% from the prior-year quarter. The consensus mark for quarterly earnings has increased by a penny in the past seven days to $7.09 per share, indicating an increase of 14.9% from the figure reported in the year-ago quarter.
CLX has a trailing four-quarter earnings surprise of 14.7%, on average, including a 7.6% negative surprise in the last reported quarter.
Things to Know Ahead of CLX’s Q4 Earnings
Clorox appears well-positioned ahead of its fourth-quarter fiscal 2025 earnings release, supported by its strategic focus on innovation, cost discipline, and brand equity in essential categories. The company continues to execute its IGNITE strategy, leveraging premium innovation and price-pack architecture to align with evolving consumer preferences. Notably, Clorox’s successful launch of premium offerings such as Scentiva and enhanced ToiletWand solutions underpins its ability to drive top-line growth even in a bifurcated consumer environment. Management also reaffirmed its confidence in delivering full-year organic sales growth, aided by strength in the Cleaning and Food categories.
A key area of resilience lies in Clorox’s continued margin expansion and operational efficiency. The company achieved its 10th consecutive quarter of gross margin growth in third-quarter fiscal 2025, which provides a solid foundation for earnings stability amid external headwinds. Through its holistic margin management program and disciplined promotional strategies, Clorox has mitigated cost pressures effectively.
For fourth-quarter fiscal 2025, gross margin is projected to be around 44%, consistent with the full-year average, despite anticipated tariff-related costs and ERP transition expenses. Moreover, the recent inventory build by retailers in anticipation of Clorox’s upcoming ERP system change could provide temporary uplift in reported sales.
Our model predicts adjusted operating profit to increase 27% year over year to $391.2 million. The operating margin is expected to expand 400 basis points (bps) to 20.2%.
The International segment also presents growth potential, with the company selectively investing in profitable platforms and markets. While the consumer environment remains under strain, Clorox's brands continue to maintain strong household penetration globally, and premium positioning has insulated them from major trade-down behavior. Retail partnerships are reportedly stable, with retailers actively managing supply chains in sync with Clorox’s transition timeline. Although category performance remains volatile, Clorox’s trusted brand portfolio and strong execution capabilities allow it to navigate challenges more effectively than many peers.
However, Clorox continues to operate in a challenging macroeconomic environment where consumers face ongoing financial pressures. The company has been contending with increased advertising expenses essential for maintaining brand visibility, which have weighed on its profitability. Clorox faces stiff competition in the consumer goods sector, which further pressures its market share and operational performance. The company is also contending with early impacts from tariffs and elevated selling, general, and administrative (SG&A) costs tied to its ongoing digital and ERP investments.
What the Zacks Model Unveils for CLX
Our proven model does not conclusively predict an earnings beat for Clorox this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Clorox currently has an Earnings ESP of -3.62% and a Zacks Rank of 5 (Strong Sell).
CLX’s Price Performance & Valuation
From a valuation perspective, CLX stock is trading at a discount relative to the industry. CLX has a forward 12-month price-to-earnings ratio of 19.50x, below the Consumer Products - Staples industry’s average of 20.20x.
CLX P/E Valuation
Image Source: Zacks Investment Research
CLX has lost 21.6% in the year-to-date period, underperforming its industry’s decline of 2.4% in the same period. Furthermore, Clorox’s performance has lagged the broader Consumer Staples sector’s 5.4% growth and the S&P 500's 8.3% decrease in the same period.
CLX Stock's Price Performance
Image Source: Zacks Investment Research
More Stocks With the Favorable Combination
Here are a few more companies, which, according to our model, have the right combination of elements to beat on earnings this reporting cycle.
The Zacks Consensus Estimate for quarterly EPS is pegged at 85 cents, which implies a roughly 8.6% decrease year over year. CHD has a trailing four-quarter earnings surprise of roughly 7.3%, on average. The Zacks Consensus Estimate for Church & Dwight’s second-quarter 2025 revenues is pegged at $1.48 billion, indicating a decline of 2.2% from the figure reported in the prior-year quarter.
Anheuser-Busch InBev SA/NV (BUD - Free Report) , alias AB InBev, has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present. BUD is likely to register a bottom-line increase when it releases second-quarter 2025 results. The consensus estimate for AB InBev’s quarterly earnings has risen by 2 cents in the past 30 days to 94 cents per share, implying a growth of 4.4% from the year-ago quarter’s number.
The Zacks Consensus Estimate for quarterly revenues is pegged at $15.3 billion, which implies a decline of 0.01% from the figure reported in the year-ago quarter. BUD delivered an earnings surprise of 10.9%, on average, in the trailing four quarters.
The Hershey Company (HSY - Free Report) currently has an Earnings ESP of +4.56% and a Zacks Rank of 3. The company is likely to register top-line growth when it reports second-quarter fiscal 2025 results. The consensus mark for Hershey’s quarterly revenues is pegged at $2.5 billion, which indicates an increase of 22.8% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for Hershey’s quarterly EPS is pegged at $1.01, indicating a 20.5% decline from the year-ago period. HSY delivered a trailing four-quarter earnings surprise of 0.6%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Clorox Pre-Q4 Earnings Send Mixed Signals: Time to Accumulate Shares?
Key Takeaways
The Clorox Company (CLX - Free Report) is slated to report fiscal fourth-quarter 2025 earnings on July 31, after market close. The company is expected to register year-over-year top-and-bottom-line growth when it posts fourth-quarter numbers.
The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $1.94 billion, indicating an increase of 2% from the prior-year quarter. The consensus mark for quarterly earnings per share (EPS) has increased by a penny in the past seven days to $2.25 per share, indicating an increase of 23.6% from the figure reported in the year-ago quarter.
The Clorox Company Price, Consensus and EPS Surprise
The Clorox Company price-consensus-eps-surprise-chart | The Clorox Company Quote
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $7.1 billion, indicating a decline of 0.5% from the prior-year quarter. The consensus mark for quarterly earnings has increased by a penny in the past seven days to $7.09 per share, indicating an increase of 14.9% from the figure reported in the year-ago quarter.
CLX has a trailing four-quarter earnings surprise of 14.7%, on average, including a 7.6% negative surprise in the last reported quarter.
Things to Know Ahead of CLX’s Q4 Earnings
Clorox appears well-positioned ahead of its fourth-quarter fiscal 2025 earnings release, supported by its strategic focus on innovation, cost discipline, and brand equity in essential categories. The company continues to execute its IGNITE strategy, leveraging premium innovation and price-pack architecture to align with evolving consumer preferences. Notably, Clorox’s successful launch of premium offerings such as Scentiva and enhanced ToiletWand solutions underpins its ability to drive top-line growth even in a bifurcated consumer environment. Management also reaffirmed its confidence in delivering full-year organic sales growth, aided by strength in the Cleaning and Food categories.
A key area of resilience lies in Clorox’s continued margin expansion and operational efficiency. The company achieved its 10th consecutive quarter of gross margin growth in third-quarter fiscal 2025, which provides a solid foundation for earnings stability amid external headwinds. Through its holistic margin management program and disciplined promotional strategies, Clorox has mitigated cost pressures effectively.
For fourth-quarter fiscal 2025, gross margin is projected to be around 44%, consistent with the full-year average, despite anticipated tariff-related costs and ERP transition expenses. Moreover, the recent inventory build by retailers in anticipation of Clorox’s upcoming ERP system change could provide temporary uplift in reported sales.
Our model predicts adjusted operating profit to increase 27% year over year to $391.2 million. The operating margin is expected to expand 400 basis points (bps) to 20.2%.
The International segment also presents growth potential, with the company selectively investing in profitable platforms and markets. While the consumer environment remains under strain, Clorox's brands continue to maintain strong household penetration globally, and premium positioning has insulated them from major trade-down behavior. Retail partnerships are reportedly stable, with retailers actively managing supply chains in sync with Clorox’s transition timeline. Although category performance remains volatile, Clorox’s trusted brand portfolio and strong execution capabilities allow it to navigate challenges more effectively than many peers.
However, Clorox continues to operate in a challenging macroeconomic environment where consumers face ongoing financial pressures. The company has been contending with increased advertising expenses essential for maintaining brand visibility, which have weighed on its profitability. Clorox faces stiff competition in the consumer goods sector, which further pressures its market share and operational performance. The company is also contending with early impacts from tariffs and elevated selling, general, and administrative (SG&A) costs tied to its ongoing digital and ERP investments.
What the Zacks Model Unveils for CLX
Our proven model does not conclusively predict an earnings beat for Clorox this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Clorox currently has an Earnings ESP of -3.62% and a Zacks Rank of 5 (Strong Sell).
CLX’s Price Performance & Valuation
From a valuation perspective, CLX stock is trading at a discount relative to the industry. CLX has a forward 12-month price-to-earnings ratio of 19.50x, below the Consumer Products - Staples industry’s average of 20.20x.
CLX P/E Valuation
Image Source: Zacks Investment Research
CLX has lost 21.6% in the year-to-date period, underperforming its industry’s decline of 2.4% in the same period. Furthermore, Clorox’s performance has lagged the broader Consumer Staples sector’s 5.4% growth and the S&P 500's 8.3% decrease in the same period.
CLX Stock's Price Performance
Image Source: Zacks Investment Research
More Stocks With the Favorable Combination
Here are a few more companies, which, according to our model, have the right combination of elements to beat on earnings this reporting cycle.
Church & Dwight (CHD - Free Report) currently has an Earnings ESP of +0.44% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly EPS is pegged at 85 cents, which implies a roughly 8.6% decrease year over year. CHD has a trailing four-quarter earnings surprise of roughly 7.3%, on average. The Zacks Consensus Estimate for Church & Dwight’s second-quarter 2025 revenues is pegged at $1.48 billion, indicating a decline of 2.2% from the figure reported in the prior-year quarter.
Anheuser-Busch InBev SA/NV (BUD - Free Report) , alias AB InBev, has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present. BUD is likely to register a bottom-line increase when it releases second-quarter 2025 results. The consensus estimate for AB InBev’s quarterly earnings has risen by 2 cents in the past 30 days to 94 cents per share, implying a growth of 4.4% from the year-ago quarter’s number.
The Zacks Consensus Estimate for quarterly revenues is pegged at $15.3 billion, which implies a decline of 0.01% from the figure reported in the year-ago quarter. BUD delivered an earnings surprise of 10.9%, on average, in the trailing four quarters.
The Hershey Company (HSY - Free Report) currently has an Earnings ESP of +4.56% and a Zacks Rank of 3. The company is likely to register top-line growth when it reports second-quarter fiscal 2025 results. The consensus mark for Hershey’s quarterly revenues is pegged at $2.5 billion, which indicates an increase of 22.8% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for Hershey’s quarterly EPS is pegged at $1.01, indicating a 20.5% decline from the year-ago period. HSY delivered a trailing four-quarter earnings surprise of 0.6%, on average.